申请人:Yoshitomi Pharmaceutical Industries, Ltd.
公开号:EP0292923A2
公开(公告)日:1988-11-30
Piperidine compounds of the formula:
or isomers thereof as well as pharmaceutically acceptable salt and/or hydrate forms thereof, and piperidine compounds of the formula:
or isomers thereof as well as salt and/or hydrate forms thereof.
In the above formulae, A represents a methylene group, an oxygen atom or a sulfur atom; B represents an oxygen atom or a sulfur atom; R¹ and R² independently represent a hydrogen atom, a lower alkyl group or an aralkyl group; R³ represents a hydrogen atom or an amino protecting group; Z represents an amino group or a protected amino group, a hydroxy group, or a reactive atom or group; m represents 1 or 2; and n represents the integer of 0 to 3.
Piperidine compounds (I) possess an inhibitory activity against angiotensin-converting enzyme, and exhibit a long lasting hypotensive activity and are useful as anti-hypertensive agents. Piperidine compounds (II) are useful as intermediates for said piperidine compounds (I).
式中的哌啶化合物
或其异构体以及其药学上可接受的盐和/或水合物形式,以及式中的哌啶化合物:
或其异构体以及它们的盐和/或水合物形式。
在上式中,A 代表亚甲基、氧原子或硫原子;B 代表氧原子或硫原子;R¹ 和 R² 独立地代表氢原子、低级烷基或芳烷基;R³ 代表氢原子或氨基保护基;Z 代表氨基或氨基保护基、羟基或活性原子或基团;m 代表 1 或 2;n 代表 0 至 3 的整数。
哌啶化合物(I)具有抑制血管紧张素转换酶的活性,并表现出持久的降压活性,可用作抗高血压药物。哌啶化合物(II)可作为上述哌啶化合物(I)的中间体。